Oligodendroglial neoplasms with ganglioglioma-like maturation: A diagnostic pitfall

Acta Neuropathologica

Volumn 120, Issue 2, 2010, Pages 237-252

  Perry, Arie ^a   Burton, Stephanie S ^a   Fuller, Gregory N ^b   Robinson, Christopher A ^c   Palmer, Cheryl A ^d   Resch, Lothar ^e   Bigio, Eileen H ^f   Gujrati, Meena ^g   Rosenblum, Marc K ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anaplasia; FISH; Ganglioglioma; Immunohistochemistry; Neuronal; Oligodendroglioma

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOTRETINOIN; KI 67 ANTIGEN; MARIMASTAT; TEMOZOLOMIDE; NEUROFILAMENT PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER GRADING; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NISSL SUBSTANCE; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR RECURRENCE; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY;

ADULT; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GANGLIOGLIOMA; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES;

EID: 77957267617     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0695-9     Document Type: Article

References (41)

1. Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of lp/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242-251
2. Alleganza A, Piled S, Frank G, Ferracini R (1990) Cerebral ganglioglioma with anaplastic oligodendroglial component. Histopathology 17:439-441
3. Bailey P, Buey PC (1929) Oligodendrogliomas of the brain, J Pathol Bacteriol 32:735-751
4. Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Ketsch T, Wolf HK, Schramm J, Elger CE, Wiestler OD (1999) The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol (Berl) 97:481-490
5. Blumcke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, Wiestler OD, Reifenberger G (2001) Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 60:984-993
6. Blumcke I, Wiestler OD (2002) Gangliogliomas: an intriguing tumor entity associated with focal, epilepsies. J Neuropathol Exp Neurol 61:575-584
7. Blumcke I, Muller S, Buslei R, Riederer BM, Wiestler OD (2004) Microtubule-associated protein-2 immunoreactivity: a useful, tool, in. the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol (Berl) 108:89-96
8. Caimcross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
9. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl. Cancer Inst 90:1473-1479
10. Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A, Sarkar C (2006) Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol. Appl. Neurobiol 32:461-468
11. Ducray F, Idbaih A, de Rey nies A, Bieche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre O, Delattre JY, Sanson M (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7:41
12. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A (2004) Prognostic value of Ip, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322
13. Ferrer-Luna R, Mata M, Nunez L, Calvar J, Dasi F, Arias E, Piquer J, Cerda-Nicolas M, Taratuto AL, Sevlever G, Celda B, Martinetto H (2009) Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol 95:343-354
14. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369
15. Hakim R, Loeffler JS, Anthony DC, Black PM (1997) Gangliogliomas in adults. Cancer 79:127-131
16. Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C, Radiwim mer B, Lichter P, Schramm J, Becker AJ, Weber RG (2008) Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol 18:326-337
17. Johnson MD, Jennings MT, Toms ST (2001) Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus. Pediatr Neurosurg 34:301-305
18. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ (2009) Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 11:737-746
19. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M (2008) Tumor recurrence and malignant progression of gangliogliomas. Cancer 113:3355-3363
20. Makuria AT, Henderson FC, Rushing EJ, Hartmann DP, Azumi N, Ozdemirli M (2007) Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor. J Neurooncol 82:199-205
21. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed highgrade gliomas. J Clin Oncol 24:5419-5426
22. Mrak RE, Yasargil MG, Mohapatra G, Earel J Jr, Louis DN (2004) Atypical extraventricular neurocytoma with oligodendroglioma-like spread and an unusual pattern of chromosome 1p and 19q loss. Hum Pathol 35:1156-1159
23. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, Nishikawa R, Asai A, Kirino T, Aburatani H (2004) Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome Ip loss. Brain Pathol 14:34-42
24. Mut M, Guler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE (2005) Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol 24:225-229
25. Ng HK, Ko H, Tse C (1994) Immunohistochemical and ultrastructural studies of oligodendrogliomas revealed features of neuronal differentiation. Int J Surg Pathol 2:47-56
26. Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A (2007) Malignant and benign ganglioglioma: a pathological, and molecular study. Neuro Oncol 9:124-134
27. Patt S, Labrakakis C, Bernstein M, Weydt P, Cervos-Navarro J, Nisch G, Kettenmann H (1996) Neuron-like physiological properties of cells from human oligodendroglial tumors. Neuroscience 71:601-611 (Pubitemid 26067022)
28. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol. 61:947-955
29. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for Ip and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:al-a9
30. Reifenberger G, Kros JM, Louis DN, Collins VP (2007) Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 54-59
31. Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and Ip. Am J Pathol 145:1175-1190
32. Shafit-Zagardo B, Davies P, Rockwood J, Kress Y, Lee SC (2000) Novel microtubule-associated protein-2 isoform is expressed early in human oligodendrocyte maturation. OHa 29:233-245
33. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms Ip and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645
34. Suzuki SO, Kitai R, Llena J, Lee SC, Goldman JE, Shafit-Zagardo B (2002) MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 61:403-412
35. Urbach H (2008) MRI of long-term epilepsy-associated tumors. Semin Ultrasound CT MR 29:40-46
36. Vajtai I, Arnold M, Vassella E (2005) Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes Ip and 19q. Acta Neuropathol (Berl) 110:520-522
37. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:271.5-2722
38. Vyberg M, Ulhoi BP, Teglbjaerg PS (2007) Neuronal features of oligodendrogliomas-an ultrastructural, and immunohistochemical study. Histopathology 50:887-896
39. Wharton SB, Chan KK, Hamilton FA, Anderson JR (1998) Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol 24:302-308
40. Wolf HK, Buslei R, Blumcke I et al (1997) Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors. Acta Neuropathol (Berl) 94:436-443
41. Yin XL, Hui AB, Pang JC, Poon WS, Ng HK (2002) Genomewide survey for chromosomal imbalances in ganglioglioma using comparative genomic hybridization. Cancer Genet Cytogenet 134:71-76